The preliminary data for the J&J trial is out! We have been waiting on this since it is a one-shot dose (rather than a two-shot dose like the mRNA vaccines). This vaccine is an adenovirus-vaccine, which is more of a “traditional” vaccine many people are used to.
✅ Here’s the highlights:
-Study participants in the trial received a low-dose shot or a high-dose shot.
-Side effects were mild and similar to the other vaccines we have. Most frequent were injection site soreness, fatigue, and mild fever.
-90% had neutralizing-antibody titers on day 29. -100% of participants had neutralizing antibodies within 57 days of the shot. Woohoo!
-Antibody levels stayed high for at least 71 days and the study is ongoing to see how long this continues. -Phase 3 data is currently being analyzed on the larger 45,000 person trial and expected to be released in a few weeks.
-US EAU application and process (similar to the process we saw with Pfizer and Moderna) is expected next month – but the firm is running behind on its production schedule.
This could be a game changer since it is only one shot. It also increases the availability of vaccines candidates.
NEJM article: https://www.nejm.org/doi/full/10.1056/NEJMoa2034201